Navigation Links
Unilife Announces Results of 2013 Annual General Meeting
Date:11/22/2013

YORK, Pa., Nov. 22, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) today announced that all of the proposed items for its 2013 Annual General Meeting of stockholders were approved by the Company's shareholders. 

The Company also announced changes to the Board of Directors and management team, including the appointment of Alan Shortall to Chairman of the Board of Directors, following Slavko James Joseph (Jim) Bosnjak's decision to step down from the position for both personal and professional reasons.  Mr. Bosnjak will remain on the Board as Deputy Chairman and Lead Independent Director. Mr. Shortall will retain his role as CEO of Unilife. Dr. Ramin Mojdeh was appointed President of the Company, and will retain his position as Chief Operating Officer.

The Company has posted a complete audio archive of the meeting, along with the slide show presentation from Unilife CEO Mr. Alan Shortall focusing on the Company's commercial pipeline on its website at http://ir.unilife.com/events.cfm

"I have tirelessly worked with Jim to accomplish great things for Unilife. And I speak for everyone at the Company, including the other members of the Board, when saying that we are lucky to have convinced Jim to remain with us as Deputy Chairman," said Mr. Shortall.  "I would also like to thank the members of the board of directors for their confidence and appointing me Chairman.  I believe that being Chairman and CEO will have some clear, near-term benefits in the negotiation of contracts."

"I would like to congratulate Ramin on his appointment to President. He has been a driving force behind our rapid ascent to the top of the drug delivery systems business and his work ethic, experience and leadership have been instrumental in our success at the negotiating table," continued Mr. Shortall.

"Over the coming months, we will continue to build upon our accomplishments and sign additional contracts with a series of pharmaceutical customers that will capture more market share for Unilife. We expect most of these will include upfront cash and recurring payments.  Moving forward, we expect sequential quarterly growth in fiscal year 2014, and significant annual growth year over prior year for fiscal year 2014 and beyond."

About Unilife Corporation Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, intraocular delivery systems and novel devices. Each of these innovative, differentiated technology platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

General: UNIS-G Investor / PR Contacts (US):
Analyst EnquiriesInvestor Contacts (Australia)Todd Fromer / Garth RussellLynn PieperJeff CarterKCSA Strategic Communications 

Westwicke Partners 

Unilife CorporationP: + 1 212-682-63P: + 1 415-202-5678P: + 61 2 8346 6500
'/>"/>

SOURCE Unilife Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife Signs Long-Term Supply Agreement with Hikma to Enhance Delivery of Generic Injectables
2. Unilife Corporation Announces Financial Results For Fiscal Year 2014 First Quarter
3. Unilife Announces Supply Agreement with MedImmune for Wearable Injectable Drug Delivery Devices
4. Unilife Issues Letter to Stockholders Regarding Securities Class Action Lawsuit
5. Unilife Corporation To Announce Financial Results For Fiscal 2014 First Quarter Monday, November 11, 2013
6. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Fourth Quarter
7. Unilife to Present at the Morgan Stanley Global Healthcare Conference in New York City on September 11th
8. Unilife Corporation To Announce Financial Results For Fiscal Year 2013 Fourth Quarter And Year End On Tuesday, September 10, 2013
9. Early Morning Insight: Baxter, CareFusion, Unilife, and Mindray Medical
10. Unilife Launches New Corporate Website
11. Unilife to Present at the Jefferies 2013 Global Healthcare Conference in New York City on June 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25, 2016  Granger Diagnostics today announced immediate availability ... and infections. This test ensures discovery of ALL ... The test requires only a simple swab of the ... David G. Bostwick , MD, Chief Medical Officer, ... healing: "We are excited to make available, for ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... 2016 Cirujanos holandeses han puesto ... los médicos a compartir sus mejores prácticas por el ... Profesionales médicos de Europa, África, Asia ... la aplicación, que combina la transmisión en vivo con ... Educación   "Imagine un médico de ...
Breaking Medicine Technology:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities ... within the industry, from leading advocates, associations and industry leaders such as Bioness. ...
(Date:5/27/2016)... ... 2016 , ... Each year Standard Process Inc. ... this year’s Life University winner of a $2,500 scholarship from Standard ... Awards ceremony. , Outerbridge is approaching her last quarter at Life University in ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and 3M ... to court documents and SEC filings. A jury has returned a verdict ... Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 ...
(Date:5/26/2016)... ... 2016 , ... The Woodlands at John Knox Village , Florida’s first ... for living and healing, celebrated its grand opening, today. The Woodlands at John Knox ... by Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... Retinal Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June 4, ... the public. , Dr. Maisel, founder of Retina Group of New York ...
Breaking Medicine News(10 mins):